These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 31708469)

  • 1. Predicting Response to Neoadjuvant Chemotherapy in Bladder Cancer.
    Motterle G; Andrews JR; Morlacco A; Karnes RJ
    Eur Urol Focus; 2020 Jul; 6(4):642-649. PubMed ID: 31708469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of Complete Pathologic Response (pT0) to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Carcinoma.
    Pokuri VK; Syed JR; Yang Z; Field EP; Cyriac S; Pili R; Levine EG; Azabdaftari G; Trump DL; Guru K; George S
    Clin Genitourin Cancer; 2016 Feb; 14(1):e59-65. PubMed ID: 26508364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant Chemotherapy in Variant Histology Bladder Cancer: Current Evidence.
    Daneshmand S; Nazemi A
    Eur Urol Focus; 2020 Jul; 6(4):639-641. PubMed ID: 32451316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [ypT0N0 after neoadjuvant chemotherapy and cystectomy for muscle-invasive bladder cancer: Incidence and prognosis. A review from the Bladder group of the French Committee of Oncology].
    Pignot G; Houédé N; Roumiguié M; Audenet F; Brunelle S; Colin P; Compérat E; Larré S; Masson-Lecomte A; Neuzillet Y; Xylinas E; Méjean A; Rouprêt M;
    Prog Urol; 2018 Oct; 28(12):567-574. PubMed ID: 30205925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Do amount of variant differentiation and mitotic rate in bladder cancer change with neoadjuvant chemotherapy?
    Shen HM; D'Souza AM; Green IF; Pohar KS; Mortazavi A; Zynger DL
    Hum Pathol; 2015 Sep; 46(9):1367-75. PubMed ID: 26232112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Rate of Neoadjuvant Chemotherapy Use in Muscle Invasive Bladder Cancer and The Approach of Urologists in Turkey.
    Üçer O; Albaz AC; Atag E; Karaoglu A; Muezzinoglu T
    Urol J; 2016 Oct; 13(5):2841-2844. PubMed ID: 27734426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant and adjuvant treatments in muscle-invasive bladder cancer: Where are we?
    Osanto S; Álvarez Gómez de Segura C
    Arch Esp Urol; 2020 Dec; 73(10):971-985. PubMed ID: 33269716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modeling 1-year Relapse-free Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients with Clinical T2-4N0M0 Urothelial Bladder Carcinoma: Endpoints for Phase 2 Trials.
    Bandini M; Briganti A; Plimack ER; Niegisch G; Yu EY; Bamias A; Agarwal N; Sridhar SS; Sternberg CN; Vaishampayan U; Théodore C; Rosenberg JE; Bellmunt J; Galsky MD; Montorsi F; Necchi A
    Eur Urol Oncol; 2019 May; 2(3):248-256. PubMed ID: 31200838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant chemotherapy prior to radical cystectomy for muscle-invasive bladder cancer with variant histology.
    Vetterlein MW; Wankowicz SAM; Seisen T; Lander R; Löppenberg B; Chun FK; Menon M; Sun M; Barletta JA; Choueiri TK; Bellmunt J; Trinh QD; Preston MA
    Cancer; 2017 Nov; 123(22):4346-4355. PubMed ID: 28743155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunological tumor status may predict response to neoadjuvant chemotherapy and outcome after radical cystectomy in bladder cancer.
    Tervahartiala M; Taimen P; Mirtti T; Koskinen I; Ecke T; Jalkanen S; Boström PJ
    Sci Rep; 2017 Oct; 7(1):12682. PubMed ID: 28978923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimization of Patient Selection for Neoadjuvant Chemotherapy in Muscle-invasive Urothelial Carcinoma of the Bladder.
    Hensley PJ; Goodwin J; Davenport DL; Strup SE; James A
    Clin Genitourin Cancer; 2018 Aug; 16(4):e851-e858. PubMed ID: 29548614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathological downstaging following radical cystectomy for muscle-invasive bladder cancer: Survival outcomes in the setting of neoadjuvant chemotherapy versus transurethral resection only.
    Cajipe M; Wang H; Elshabrawy A; Kaushik D; Liss M; Svatek R; Wu S; Chowdhury WH; Ramamurthy C; Mansour AM
    Urol Oncol; 2020 Apr; 38(4):231-239. PubMed ID: 31956078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficient delivery of radical cystectomy after neoadjuvant chemotherapy for muscle-invasive bladder cancer: a multidisciplinary approach.
    Alva AS; Tallman CT; He C; Hussain MH; Hafez K; Montie JE; Smith DC; Weizer AZ; Wood D; Lee CT
    Cancer; 2012 Jan; 118(1):44-53. PubMed ID: 21598245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A delay ≥8 weeks to neoadjuvant chemotherapy before radical cystectomy increases the risk of upstaging.
    Audenet F; Sfakianos JP; Waingankar N; Ruel NH; Galsky MD; Yuh BE; Gin GE
    Urol Oncol; 2019 Feb; 37(2):116-122. PubMed ID: 30509868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between precystectomy epithelial tumor marker response to neoadjuvant chemotherapy and oncological outcomes in urothelial bladder cancer.
    Bazargani ST; Clifford TG; Djaladat H; Schuckman AK; Wayne K; Miranda G; Cai J; Sadeghi S; Dorff T; Quinn DI; Daneshmand S
    Urol Oncol; 2019 Jan; 37(1):1-11. PubMed ID: 30470611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cell-free DNA Methylation as a Predictive Biomarker of Response to Neoadjuvant Chemotherapy for Patients with Muscle-invasive Bladder Cancer in SWOG S1314.
    Lu YT; Plets M; Morrison G; Cunha AT; Cen SY; Rhie SK; Siegmund KD; Daneshmand S; Quinn DI; Meeks JJ; Lerner SP; Petrylak DP; McConkey D; Flaig TW; Thompson IM; Goldkorn A
    Eur Urol Oncol; 2023 Oct; 6(5):516-524. PubMed ID: 37087309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low Pretreatment Neutrophil-to-Lymphocyte Ratio Predicts for Good Outcomes in Patients Receiving Neoadjuvant Chemotherapy Before Radical Cystectomy for Muscle Invasive Bladder Cancer.
    Buisan O; Orsola A; Areal J; Font A; Oliveira M; Martinez R; Ibarz L
    Clin Genitourin Cancer; 2017 Feb; 15(1):145-151.e2. PubMed ID: 27364982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between Smoking Exposure, Neoadjuvant Chemotherapy Response and Survival Outcomes following Radical Cystectomy: Systematic Review and Meta-Analysis.
    Cacciamani GE; Ghodoussipour S; Mari A; Gill KS; Desai M; Artibani W; Gill PS; Shariat SF; Gill IS; Djaladat H
    J Urol; 2020 Oct; 204(4):649-660. PubMed ID: 32105187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomised phase III study of neoadjuvant chemotherapy with methotrexate, doxorubicin, vinblastine and cisplatin followed by radical cystectomy compared with radical cystectomy alone for muscle-invasive bladder cancer: Japan Clinical Oncology Group Study JCOG0209.
    Kitamura H; Tsukamoto T; Shibata T; Masumori N; Fujimoto H; Hirao Y; Fujimoto K; Kitamura Y; Tomita Y; Tobisu K; Niwakawa M; Naito S; Eto M; Kakehi Y;
    Ann Oncol; 2014 Jun; 25(6):1192-8. PubMed ID: 24669010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Complete Response after Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer: A Call for Standardized Assessments and Definitions.
    Winoker JS; Liaw CW; Galsky MD; Wiklund P; Mehrazin R
    Eur Urol Focus; 2020 Jul; 6(4):627-629. PubMed ID: 31494093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.